GI manifestations of 58 patients with SARS-CoV-2 infection
| All patients (n=58) | On initial presentation (n=11) | During hospitalisation (n=47) | |
| Symptoms | |||
| Diarrhoea | 23 (24.2) | 5 (5.3) | 18 (18.9) |
| Anorexia | 17 (17.9) | 5 (5.3) | 12 (12.6) |
| Nausea | 17 (17.9) | 3 (3.2) | 14 (14.7) |
| Vomiting | 4 (4.2) | 0 | 4 (4.2) |
| Acid reflux | 2 (2.1) | 1 (1.1) | 1 (1.1) |
| Epigastric discomfort | 2 (2.1) | 0 | 2 (2.1) |
| Upper GI haemorrhage | 2 (2.1) | 0 | 2 (2.1) |
| Hepatic function impairment | 31 (32.6) | 1 (1.1) | 30 (31.6) |
| Total bilirubin (μmol/L; normal range 3.0–24.0) | 11.4±3.6 (37.7±18.2) | ||
| Increased | 22 (23.2) | 0 | 22 (23.2) |
| ALT (U/L; normal range 7–40 in female, 9–50 in male) | 22.5±19.2 (91.8±31.5) | ||
| Increased | 5 (5.3) | 1 (1.1) | 4 (4.2) |
| AST (U/L; normal rage 13–35 in female, 15–40 in male) | 17.6±5.6 (73.2±19.0) | ||
| Increased | 4 (4.2) | 0 | 4 (4.2) |
Data are presented as n (%) and mean±SD on initial presentation (maximum value during hospitalisation). % is the percentage in 95 patients.
ALT, alanine aminotransferase; AST, aspartate transaminase; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.